Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer – Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 147, 100, 8, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 7 and 3 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

A28 Therapeutics Inc
Aadi Bioscience Inc
Ability Pharmaceuticals SL
ABL Bio Inc
Abpro Corp
Acrivon Therapeutics Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Agenus Inc
Akeso Inc
Alaunos Therapeutics Inc
Alkermes Plc
Allarity Therapeutics Inc
Alligator Bioscience AB
Almac Discovery Ltd
Alphamab Oncology
ALX Oncology Holdings Inc
Ambrx Biopharma Inc
Amgen Inc
Aminex Therapeutics Inc
Amphivena Therapeutics Inc
Apexian Pharmaceuticals Inc
Apexigen Inc
Apollomics Inc
Arch Oncology Inc
Arcus Biosciences Inc
Ascenta Therapeutics Inc
AstraZeneca Plc
Bantam Pharmaceutical LLC
Basilea Pharmaceutica Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bellicum Pharmaceuticals Inc
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
BioAtla Inc
BioMed Valley Discoveries Inc
BioNTech SE
Biosion Inc
Biosplice Therapeutics Inc
Biotheus Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Byondis BV
Calithera Biosciences Inc
CanBas Co Ltd
Carrick Therapeutics Ltd
Celon Pharma SA
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimerix Inc
Clovis Oncology Inc
Coherent Biopharma
Compugen Ltd
Context Therapeutics Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Cue Biopharma Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Ella Therapeutics Ltd
Elucida Oncology Inc
ENB Therapeutics LLC
EpimAb Biotherapeutics Inc
Esperas Pharma Inc
EstryX Pharma Ltd
Exelixis Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
Genelux Corp
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
Gradalis Inc
Greenfire Bio LLC
GSK plc
Guangzhou Yinming Biomedical Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Horizon Therapeutics Plc
Huabo Biopharm (Shanghai) Co Ltd
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
Idience Co Ltd
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunocore Limited
ImmunoGen Inc
Immvira Co Ltd
IMPACT Therapeutics Inc
Imunon Inc
Imvax Inc
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
Inspirna Inc
Instil Bio Inc
iTeos Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Komipharm International Co Ltd
L&L Biopharma Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
LegoChem Biosciences Inc
Light Chain Bioscience
MedGene Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
MorphoSys AG
NeoTX Therapeutics Ltd
Netris Pharma SAS
NextCure Inc
Northlake International LLC
Novartis AG
Novita Pharmaceuticals Inc
Nurix Therapeutics Inc
Nuvation Bio Inc
Nuvectis Pharma Inc
Olema Pharmaceuticals Inc
OncoQuest Inc
OncoResponse Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Otsuka Pharmaceutical Co Ltd
Pano Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Pionyr Immunotherapeutics Inc
Portage Biotech Inc
Precision Biologics Inc
Prelude Therapeutics Inc
PRISM Pharma Co Ltd
ProfoundBio Suzhou Co Ltd
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Qurient Co Ltd
RemeGen Co Ltd
Repare Therapeutics Inc
Rhizen Pharmaceuticals SA
Salarius Pharmaceuticals Inc
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Shandong Boan Biotechnology Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Simcha Therapeutics Inc
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Splash Pharmaceuticals Inc
SpringWorks Therapeutics Inc
Sutro Biopharma Inc
Suzhou Maximum Bio-tech Co Ltd
Suzhou Neupharma Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
SynOx Therapeutics Ltd
Taiho Pharmaceutical Co Ltd
TCR Cure Biopharma Technology Co Ltd
Tempest Therapeutics Inc
Theratechnologies Inc
TORL Biotherapeutics LLC
Treadwell Therapeutics Inc
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
Tyra Biosciences Inc
Verastem Inc
Vincerx Pharma Inc
Vyriad Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Xencor Inc
Xynomic Pharmaceuticals Holdings Inc
Y-Biologics Inc
Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Endometrial Cancer – Overview

Endometrial Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Endometrial Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Endometrial Cancer – Companies Involved in Therapeutics Development

Endometrial Cancer – Drug Profiles

Endometrial Cancer – Dormant Projects

Endometrial Cancer – Discontinued Products

Endometrial Cancer – Product Development Milestones

Featured News & Press Releases

Sep 29, 2022: Imvax presents new data on personalized whole-tumor derived immunotherapeutic platform at 2022 International Cancer Immunotherapy Conference

Sep 13, 2022: Eisai presents new data on lenvatinib from its oncology portfolio and pipeline at ESMO Congress 2022

Aug 17, 2022: Mersana begins dosing in Phase I solid tumour therapy trial

Aug 03, 2022: ProfoundBio receives FDA “Study May Proceed” Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 inhibitor payload, and welcomes Naomi Hunder, M.D., as Chief Medical Officer

Jul 14, 2022: Theratechnologies provides update on the dose escalation portion of Fast Track designated TH1902 first-in-human study in advanced resistant malignancies

Jul 12, 2022: Leap Therapeutics announces initiation of new DKN-01 clinical trials in gastric cancer, colorectal cancer and endometrial cancer

Jun 27, 2022: Harbour BioMed announces IND clearance for B7H4x4-1BB bispecific antibody by the U.S. Food and Drug Administration

Jun 03, 2022: Made-in-Singapore cancer drug ETC-159 advances in clinical trials

May 26, 2022: Karyopharm to present new Selinexor data at the 2022 American Society of Clinical Oncology Annual Meeting

May 11, 2022: Amber Specialty Pharmacy added to Eisai’s LENVIMA Network

May 05, 2022: Context Therapeutics announces poster presentation at the upcoming 2022 ASCO Annual Meeting

Apr 28, 2022: Clovis Oncology highlights Rubraca data to be presented at 2022 ASCO Annual Meeting

Apr 27, 2022: Karyopharm announces selinexor data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting

Apr 08, 2022: Sutro Biopharma presents nonclinical data for antibody-drug conjugate STRO-002 at the AACR Annual Meeting 2022

Apr 05, 2022: Nurix Therapeutics doses first patient in phase 1 clinical trial of DeTIL-0255, a drug-enhanced cell therapy for the treatment of patients with solid tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Endometrial Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Endometrial Cancer – Dormant Projects, 2022

Endometrial Cancer – Discontinued Products, 2022

Endometrial Cancer – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Endometrial Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.